Skip to main content

Table 4 Proportion of children with 8-fold increase of anti-MSP3 antibodies at day 84 by vaccine type

From: Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12–24 months

Antibody

15 μg MSP3

30 μg MSP3

Engerix B

 

N

n

%

N

n

%

N

n

%

Total IgG

15

4

26.7

12

4

33.3

13

1

7.7

IgG1

15

15

100

12

10

83.3

13

2

15.4

IgG2

15

0

0

12

0

0

13

0

0

IgG3

15

13

86.7

12

11

91.7

13

6

46.2

IgG4

15

3

20

12

4

33.3

13

1

7.7

  1. N = total vaccinated, n = responders